DiaMedica Therapeutics (DMAC) director granted 40,412 stock options at $5.84

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. director Randall Michael Giuffre received a grant of stock options representing 40,412 Voting Common Shares. The options have an exercise price of $5.84 per share, expire on June 1, 2036, and are scheduled to vest in four equal quarterly installments.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Giuffre Randall Michael

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	40,412	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 40,412 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 40,412 options Exercise price: $5.84 per share Expiration date: June 1, 2036 +2 more

5 metrics

Options granted 40,412 options Director stock option grant, underlying Voting Common Shares

Exercise price $5.84 per share Exercise price for granted stock options

Expiration date June 1, 2036 Option grant expiration

Total options after grant 40,412 options Total derivative position following transaction

Vesting schedule Four equal quarterly installments Footnote on option vesting terms

Key Terms

Stock Option (right to buy), Voting Common Shares, Grant, award, or other acquisition, derivative, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

Voting Common Shares financial

"underlying_security_title: "Voting Common Shares""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

derivative financial

"transaction_type: "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

vesting in four equal quarterly installments financial

"footnote: "Scheduled to vest in four equal quarterly installments.""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giuffre Randall Michael

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.84	06/01/2026		A		40,412		(1)	06/01/2036	Voting Common Shares	40,412	$0	40,412	D

Explanation of Responses:

1. Scheduled to vest in four equal quarterly installments.

	/s/ Joshua L. Colburn, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did DiaMedica Therapeutics (DMAC) report on this Form 4?

DiaMedica Therapeutics reported that director Randall Michael Giuffre received a grant of stock options for 40,412 Voting Common Shares. This is a compensation-related award, not an open-market purchase or sale of common shares.

How many DiaMedica Therapeutics (DMAC) options were granted to Randall Michael Giuffre?

Randall Michael Giuffre received stock options covering 40,412 Voting Common Shares. These options were reported as a derivative security grant on the Form 4 and represent his total option position following the transaction.

What is the exercise price of the new DiaMedica Therapeutics (DMAC) stock options?

The granted stock options have an exercise price of $5.84 per share. This is the price at which Randall Michael Giuffre can buy DiaMedica Therapeutics Voting Common Shares if he exercises the options in the future.

When do Randall Michael Giuffre’s DiaMedica Therapeutics (DMAC) options expire?

The stock options granted to Randall Michael Giuffre expire on June 1, 2036. He can choose to exercise these options any time before that expiration date, subject to vesting and any applicable company or regulatory requirements.

How do the DiaMedica Therapeutics (DMAC) options granted to Randall Giuffre vest?

The options are scheduled to vest in four equal quarterly installments. This means the 40,412-option grant becomes exercisable gradually over four quarters, aligning vesting with continued service over that period.

Is the DiaMedica Therapeutics (DMAC) Form 4 transaction a market buy or sell?

No. The Form 4 reports a grant or award acquisition of stock options, coded as “A.” It is part of director compensation and does not represent an open-market purchase or sale of DiaMedica Therapeutics common shares.